SCHEMBL1060223

SCHEMBL1060223

C[Si](C)(C)CCOCn1nnnc1-c1ccc(OCc2ccccc2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.43
ERN1 O75460 1/20 0.39
ALDH1A1 P00352 5/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
DGAT1 O75907 1/20 0.36
TSHR P16473 3/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
CTSA P10619 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
S1PR5 Q9H228 1/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1060421 0.83 ALDH1A1 (0.44) GRM2ERN1ALDH1A1HPGDSMN1; SMN2
SCHEMBL1058756 0.81 NPC1 (0.52) GRM2ERN1ALDH1A1SMN1; SMN2POLB
SCHEMBL31417870 0.81 DGAT1 (0.36) ALDH1A1HPGDSMN1; SMN2POLBHTT
SCHEMBL31417878 0.81 DGAT1 (0.36) ALDH1A1HPGDSMN1; SMN2POLBHTT
SCHEMBL1059430 0.80 ALDH1A1 (0.51) GRM2ERN1ALDH1A1SMN1; SMN2POLB
SCHEMBL1060454 0.79 ALDH1A1 (0.37) ALDH1A1HPGDPOLBHTTDGAT1
SCHEMBL732954 0.75 DGAT1 (0.43) ALDH1A1HPGDSMN1; SMN2HTTDGAT1
SCHEMBL30750559 0.74 ATM (0.35) ALDH1A1HPGDSMN1; SMN2POLBHTT
SCHEMBL27176798 0.74 ATM (0.35) ALDH1A1HPGDSMN1; SMN2POLBHTT
SCHEMBL31417915 0.74 DGAT1 (0.40) ALDH1A1HPGDSMN1; SMN2DGAT1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643310-A1 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS Pfizer Inc (US) 2013-10-02 EP disclosed
WO-2012069948-A1 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS PFIZER INC. (US) 2012-05-31 WO disclosed
EP-2438051-A1 L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS Pfizer Inc. (US) 2012-04-11 EP disclosed
US-20110020460-A1 GPR 119 MODULATORS PFIZER INC. 2011-01-27 US disclosed
WO-2010140092-A1 L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS PFIZER INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020460-A1 GPR 119 MODULATORS GPR119, GPR65, GPR88 GRM2 39/4885ERN1 4158/4885ALDH1A1 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.